Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: repaglinide
Drug: insulin NPH

First Posted Date: 2012-03-26

Last Posted Date: 2017-02-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 213

Registration Number: NCT01562561

Locations: 🇨🇳
Novo Nordisk Investigational Site, Tainan city, Taiwan

Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A
Haemophilia B

Interventions: Drug: activated recombinant human factor VII

First Posted Date: 2012-03-26

Last Posted Date: 2017-01-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 18

Registration Number: NCT01562587

Locations: 🇬🇧
Novo Nordisk Investigational Site, Oxford, United Kingdom

Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A With Inhibitors
Acquired Bleeding Disorder
Acquired Haemophilia
Glanzmann's Disease
Healthy
Congenital FVII Deficiency
Haemophilia B With Inhibitors

Interventions: Drug: activated recombinant human factor VII

First Posted Date: 2012-03-23

Last Posted Date: 2017-01-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 28

Registration Number: NCT01561417

Locations: 🇫🇷
Novo Nordisk Investigational Site, Paris, France

Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A With Inhibitors
Haemophilia B With Inhibitors

Interventions: Drug: eptacog alfa (activated)

First Posted Date: 2012-03-23

Last Posted Date: 2016-11-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 17

Registration Number: NCT01561924

Locations: 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

Phase 4

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia B With Inhibitors
Haemophilia A With Inhibitors

Interventions: Drug: activated recombinant human factor VII
Other: factor IX
Drug: factor VIII

First Posted Date: 2012-03-23

Last Posted Date: 2023-12-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT01561391

Locations: 🇺🇸
Novo Nordisk Investigational Site, Houston, Texas, United States

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation

Phase 2

Completed

Conditions: Acquired Bleeding Disorder
Bleeding During/Following Surgery

Interventions: Procedure: standard therapy
Drug: activated recombinant human factor VII
Drug: placebo

First Posted Date: 2012-03-23

Last Posted Date: 2017-01-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 100

Registration Number: NCT01562158

Locations: 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom

Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

Phase 1

Completed

Conditions: Haemostasis
Healthy

Interventions: Drug: eptacog alfa (activated)
Drug: warfarin
Drug: placebo

First Posted Date: 2012-03-23

Last Posted Date: 2016-11-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 127

Registration Number: NCT01561937

Locations: 🇺🇸
Novo Nordisk Investigational Site, Overland Park, Kansas, United States

Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State

Phase 1

Completed

Conditions: Haemophilia A
Haemophilia B
Congenital Bleeding Disorder

Interventions: Drug: activated recombinant human factor VII

First Posted Date: 2012-03-23

Last Posted Date: 2016-05-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 30

Registration Number: NCT01562457

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

Phase 1

Terminated

Conditions: Haemostasis
Healthy

Interventions: Drug: clopidogrel
Drug: eptacog alfa (activated)
Drug: placebo

First Posted Date: 2012-03-23

Last Posted Date: 2016-11-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 91

Registration Number: NCT01561950

Locations: 🇺🇸
Novo Nordisk Investigational Site, Neptune, New Jersey, United States

Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis

Phase 2

Completed

Conditions: Other Haemostasis Disorder
Haemorrhagic Cystitis

Interventions: Drug: activated recombinant human factor VII

First Posted Date: 2012-03-23

Last Posted Date: 2017-01-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 7

Registration Number: NCT01561352

Locations: 🇺🇸
Novo Nordisk Investigational Site, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy